NADAC acquisition cost data for DULOXETINE HCL DR 30 MG CAP. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00904645361 | $0.1067 | 2022-10-19 | Rx |
| 00904645361 | $0.1067 | 2022-10-19 | Rx |
| 00904645361 | $0.1067 | 2022-10-19 | Rx |
| 00228289103 | $0.1000 | 2022-12-21 | Rx |
| 00228289150 | $0.1000 | 2022-12-21 | Rx |
| 00904704461 | $0.1000 | 2022-12-21 | Rx |
| 13668011005 | $0.1000 | 2022-12-21 | Rx |
| 13668011030 | $0.1000 | 2022-12-21 | Rx |
| 27241009803 | $0.1000 | 2022-12-21 | Rx |
| 27241009809 | $0.1000 | 2022-12-21 | Rx |
Generic: Duloxetine HCl | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $424.6M | 9,956,349 | 1,950,159 | $0.7163 |
| 2020 | $405.9M | 10,733,391 | 2,018,972 | $0.6037 |
| 2021 | $414.5M | 11,009,520 | 2,168,106 | $0.5863 |
| 2022 | $503.1M | 11,480,925 | 2,291,609 | $0.6691 |
| 2023 | $398.8M | 12,210,514 | 2,465,211 | $0.4920 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.